Prostate Cancer Survival Rates: By Stage, Grade & Age

What are prostate cancer survival rates?

Survival rates tell you what percentage of people with the same type and stage of cancer are still alive after a certain period (usually 5 or 10 years). They are estimates based on large groups of patients and cannot predict individual outcomes.

Important caveats:

• Survival rates are based on patients treated 5-10 years ago. Newer treatments may improve survival.
• Most prostate cancers are slow-growing; many men die WITH prostate cancer, not FROM it.
• Your individual prognosis depends on many factors (age, overall health, cancer stage, grade).

Survival by stage – localized, regional, distant

Prostate cancer survival varies significantly by stage at diagnosis:

• Localized (Stage I-II – cancer confined to prostate): 5-year survival: >99% | 10-year survival: >98% | 15-year survival: >95%
• Regional (Stage III – spread to nearby lymph nodes): 5-year survival: >95% | 10-year survival: 85-90%
• Distant (Stage IV – metastatic, spread to bones/organs): 5-year survival: 30-40% | 10-year survival: 10-20%

Trends over time:

• Distant stage survival has improved from 20-25% (1990s) to 30-40% (2020s) due to new therapies (abiraterone, enzalutamide, docetaxel, PARP inhibitors, Lu-177-PSMA).

Survival by Gleason score – Grade Group 1-5

Gleason score (Grade Group) is the most important predictor of outcome:

• Gleason 6 (Grade Group 1 – low risk): 15-year prostate cancer-specific survival: >99%
• Gleason 3+4=7 (Grade Group 2 – favorable intermediate): 15-year prostate cancer-specific survival: 95-98%
• Gleason 4+3=7 (Grade Group 3 – unfavorable intermediate): 15-year prostate cancer-specific survival: 90-95%
• Gleason 8 (Grade Group 4 – high risk): 15-year prostate cancer-specific survival: 80-90%
• Gleason 9-10 (Grade Group 5 – very high risk): 15-year prostate cancer-specific survival: 60-80%

Clinical implication:

• Gleason 6 cancer has near-zero metastatic potential. Men with Gleason 6 rarely die from prostate cancer.
• Gleason 9-10 cancer is aggressive and requires prompt, intensive treatment.

Survival by age – younger vs. older men

Age affects survival in two ways: competing risks and cancer aggressiveness.

Competing risks:

• Older men are more likely to die from other causes (heart disease, stroke, other cancers) than from prostate cancer.
• A 75-year-old with low-risk prostate cancer has a very low chance of dying from prostate cancer (he will die from something else).

Cancer-specific survival by age (localized cancer):

• Under 50: 10-year survival >99% (but cancer may be more aggressive)
• 50-69: 10-year survival >98%
• 70-79: 10-year survival >95% (competing risks increase)
• 80+: Most men die from other causes, not prostate cancer

Survival by risk group – low, intermediate, high, metastatic

2-5%30-50%

Risk Group	5-Year Prostate Cancer-Specific Survival	10-Year Prostate Cancer-Specific Survival	Metastasis Risk (10 years)
Low	>99%	>99%	<1%
Favorable Intermediate	>99%	98%
Unfavorable Intermediate	98%	95%	10-15%
High	95%	85-90%	20-30%
Very High	90%	70-80%
Metastatic (mHSPC)	60-80%	30-50%	N/A

Factors that affect prognosis

Several factors influence prostate cancer outcomes:

• Stage (TNM): Localized vs. metastatic – most important
• Gleason score / Grade Group: Higher grade = worse prognosis
• PSA level: Higher PSA = worse prognosis (especially >20 ng/mL)
• Age and overall health: Younger, healthier men tolerate treatment better and have longer life expectancy
• Comorbidities: Heart disease, diabetes, COPD reduce life expectancy (competing risks)
• Genetic mutations (BRCA2): More aggressive cancer, but responds to PARP inhibitors
• Response to initial treatment: PSA nadir after surgery/radiation predicts recurrence

Relative survival vs. overall survival

Cancer survival statistics use two different measures:

• Overall survival: Percentage of patients alive after a certain time (includes deaths from any cause).
• Relative survival: Percentage of patients alive compared to the general population (adjusts for deaths from other causes).

Example:

• An 80-year-old with low-risk prostate cancer: 10-year overall survival might be 50% (due to other causes), but relative survival is 100% (no excess deaths from prostate cancer).

Improving survival – modern treatments

Survival for metastatic prostate cancer has improved dramatically with new therapies:

• 1990s (ADT only): mCRPC survival 12-18 months
• 2004 (docetaxel approved): mCRPC survival 18-24 months
• 2010-2015 (abiraterone, enzalutamide, cabazitaxel, radium-223): mCRPC survival 2-3 years
• 2018-2024 (PARP inhibitors, Lu-177-PSMA): mCRPC survival 3-5+ years

Future directions:

• Combination therapies (ADT + novel agents in mHSPC)
• Earlier use of chemotherapy (high-volume mHSPC)
• PSMA-targeted therapies
• Immunotherapy combinations

Interactive FAQ – Prostate cancer survival rates

---

Disclaimer: This information is for educational purposes. Survival rates are estimates and do not predict individual outcomes. Consult a urologist at Vivekananda Hospital for personalised prognosis.